- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innoviva Inc (INVA)
Innoviva Inc stock price live, this page displays NASDAQ INVA stock exchange data. View the INVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Innoviva Inc real time stock price chart below.
What Is the Innoviva Inc Stock Price Today?
The Innoviva Inc stock price today is 22.96.
What Is the Stock Symbol for Innoviva Inc?
The stock symbol for Innoviva Inc is "INVA."
What Stock Exchange Does Innoviva Inc Trade On?
Innoviva Inc is listed and trades on the NASDAQ stock exchange.
Is Innoviva Inc a Good Stock to Buy?
Determining whether Innoviva Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INVA quote. (ISIN: US45781M1018)
What Is the Innoviva Inc Stock Price Today?
The Innoviva Inc stock price today is 22.96.
What Is the Stock Symbol for Innoviva Inc?
The stock symbol for Innoviva Inc is "INVA."
What Stock Exchange Does Innoviva Inc Trade On?
Innoviva Inc is listed and trades on the NASDAQ stock exchange.
Is Innoviva Inc a Good Stock to Buy?
Determining whether Innoviva Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INVA quote. (ISIN: US45781M1018)
NASDAQ
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.65
23.88
52 wk Range
16.52
25.15
INVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
22.6523.88
52 wk Range
16.5225.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INVA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
33.20
Upside
+44.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Innoviva stock hits 52-week high at $22.81
- Investing.com
- Innoviva stock hits 52-week high at 24.02 USD
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Innoviva Inc Company Profile
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Compare INVA to Peers and Sector
Metrics to compare | INVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 6.3x | −2.2x | −0.6x | |
PEG Ratio | 0.01 | −0.04 | 0.00 | |
Price/Book | 1.5x | 1.1x | 2.6x | |
Price / LTM Sales | 4.2x | 3.8x | 3.3x | |
Upside (Analyst Target) | 52.6% | 560.9% | 44.8% | |
Fair Value Upside | Unlock | 7.2% | 5.5% | Unlock |
Analyst Ratings
4 Buy
0 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 33.20
(+44.60% Upside)
Earnings
Latest Release
Feb 26, 2026
EPS / Forecast
1.94 / 0.574
Revenue / Forecast
114.60M / 101.53M
People Also Watch
FAQ
What Is the Innoviva (INVA) Stock Price Today?
The Innoviva stock price today is 22.96 USD.
What Stock Exchange Does Innoviva Trade On?
Innoviva is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Innoviva?
The stock symbol for Innoviva is "INVA."
What Is the Innoviva Market Cap?
As of today, Innoviva market cap is 1.72B USD.
What Is Innoviva's Earnings Per Share (TTM)?
The Innoviva EPS (TTM) is 4.02.
When Is the Next Innoviva Earnings Date?
Innoviva will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is INVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Innoviva Stock Split?
Innoviva has split 0 times.
How Many Employees Does Innoviva Have?
Innoviva has 127 employees.
What is the current trading status of Innoviva (INVA)?
As of Feb 28, 2026, Innoviva (INVA) is trading at a price of 22.96 USD, with a previous close of 23.54 USD. The stock has fluctuated within a day range of 22.65 USD to 23.88 USD, while its 52-week range spans from 16.52 USD to 25.15 USD.
What Is Innoviva (INVA) Price Target According to Analysts?
The average 12-month price target for Innoviva is 33.20 USD, with a high estimate of 46 USD and a low estimate of 18 USD. 4 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +44.60% Upside potential.
What Is the INVA Premarket Price?
INVA's last pre-market stock price is 23.89 USD. The pre-market share volume is 200.00, and the stock has decreased by 0.35, or 1.49%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.